Rishi P. Singh, MD
Staff Physician and President, Cleveland Clinic
Martin Health, Cleveland Clinic Florida
Professor of Ophthalmology
Case Western Reserve University
Cleveland Clinic Lerner College of Medicine
This educational Microlearning Snapshot enduring activity focuses on the importance of genes in the pathogenesis of inherited and acquired retinal diseases and how they can be leveraged in gene therapy for the management of various retinal diseases. Additional considerations regarding risk/benefit profile, durability, feasibility and application as well as emerging advances in anti-vascular endothelial growth factor (anti-VEGF) treatment are also explored for impact on overcoming barriers related to treatment burden and adherence.
This activity is designed to meet the educational needs of clinicians in ophthalmology or retina fellowships who manage patients with retinal diseases.
After completing the CME activity, learners should be better able to:
- Describe the role genes play in the etiopathogenesis of retinal conditions
- Discuss clinical trial data on the efficacy and safety of vascular endothelial growth factor (VEGF) inhibitors and gene therapy in the management of retinal diseases
- Identify evidence-based treatment and patient selection strategies for the management of patients with retinal diseases
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education ACCME Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG‐sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF CONFLICTS OF INTEREST
Rishi P. Singh, MD discloses the following:
- Sponsored research: NGM Biopharmaceuticals
- Consulting: Bausch + Lomb, AsclepiX Therapeutics, Gyroscope, Apellis Pharmaceuticals, Genentech, Novartis, Regeneron Pharmaceuticals, and ZEISS
All relevant financial relationships have been mitigated.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
Staff, Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME/CE activity:
- Matthew Frese, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
- Nicole Longo, DO, FACOI, VP of Med/Sci Services and Learner Engagement of Med Learning Group, has nothing to disclose.
- Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP of Accreditation and Outcomes of Med Learning Group, has nothing to disclose.
- Daniel Dasilva, Accreditation and Outcomes Coordinator of Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During the course of this lecture, the faculty may mention the use of medications for both FDA‐approved and non‐approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:
- Read the CME information and faculty disclosures
- Participate in the enduring activity
- Complete pre-test andpost-test surveys and evaluation
You will receive your certificate as a downloadable file.
Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision‐making expertise before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected]
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at https://www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: March 31, 2023
EXPIRATION DATE: March 31, 2024
Copyright © 2023 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.